PPPA (drug)

PPPA (drug)

PPPA (drug)
Systematic (IUPAC) name
3-Phenoxy-3-phenyl-1-propanamine
Identifiers
ATC code None
ChemSpider
Chemical data
Formula C15H17NO
Molecular mass 227.302 g/mol

PPPA, or 3-phenoxy-3-phenylpropan-1-amine, is a drug which is described as an antidepressant.[1] It was derived by Eli Lilly from the antihistamine diphenhydramine, a 2-diphenylmethoxyethanamine derivative with additional properties as a selective serotonin reuptake inhibitor (SSRI), and has been the basis for the subsequent discovery of a number of other antidepressant drugs.[2][3][4]

Contents

  • List of PPPA derivatives 1
  • See also 2
  • References 3
  • Further reading 4

List of PPPA derivatives

  • Atomoxetine ((3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine) - NRI[1]
  • Fluoxetine (N-methyl-3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) - SSRI[2]
  • N-Methyl-PPPA (N-methyl-3-phenoxy-3-phenylpropan-1-amine) - SNRI[2][4]
  • Nisoxetine (N-methyl-3-(2-methoxyphenoxy)-3-phenylpropan-1-amine) - NRI[1]
  • Norfluoxetine (3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) - SSRI[3]
  • Seproxetine ((S)-3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) - SSRI[5]

Structurally related drugs include dapoxetine, duloxetine, edivoxetine, femoxetine, paroxetine, reboxetine, and viloxazine, all of which act, similarly, as monoamine reuptake inhibitors, and most of which are, again similarly, antidepressants.[1][3]

Zimelidine is an antidepressant and SSRI which was derived from the antihistamine pheniramine, which, similarly to its analogues brompheniramine and chlorpheniramine, possesses SNRI properties.[4] Fluvoxamine, another antidepressant and SSRI, was developed from the antihistamine tripelennamine, which possesses SNDRI actions.[6]

See also

References

  1. ^ a b c d Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 414–.  
  2. ^ a b c Francisco Lopez-Munoz; Cecilio Alamo (9 September 2011). Neurobiology of Depression. CRC Press. pp. 132–.  
  3. ^ a b c Janos Fischer; C. Robin Ganellin (24 August 2010). Analogue-based Drug Discovery II. John Wiley & Sons. pp. 35, 282, 284.  
  4. ^ a b c Walter Sneader (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 416–417.  
  5. ^ David G. Watson (9 February 2011). Pharmaceutical Chemistry. Elsevier Health Sciences. pp. 1061–.  
  6. ^ David Healy (1 June 2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. NYU Press. pp. 295–.  

Further reading

  • Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sci. 57 (5): 411–41.